PeproMene Bio, Inc. is at the forefront of developing innovative immune therapies, particularly focusing on BAFF-R CAR-T therapy, which targets the B-cell Activating Factor Receptor (BAFF-R). This receptor is predominantly expressed on B cells and plays a crucial role in their proliferation and survival. The company's lead candidate, PMB-CT01, is an autologous CAR T-cell therapy designed to treat relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma. The therapy has shown promising results in clinical trials, with patients achieving complete remission and minimal toxicity, indicating its potential effectiveness against various B-cell malignancies.

In addition to BAFF-R CAR-T therapy, PeproMene is also exploring other therapeutic avenues, including BAFF-R bispecific T-cell engagers and BAFF-R CAR natural killer (NK) cells. The BAFF-R BiTE utilizes a combination of anti-CD3 and anti-BAFF-R antibodies to enhance the immune response against tumors, while the CAR-NK cells offer a promising "off-the-shelf" treatment option due to their ability to be derived from allogeneic donors. These innovative approaches aim to address the challenges of tumor relapse and provide new hope for patients with unmet medical needs in the realm of cancer and immune disorders.

United States

PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. We are committed to developing novel therapies to treat cancers and immune disorders. Our CAR T cells targeting an innovative tumor antigen (BAFF-R) for treating a broad range of B cell malignancies have a great potential to overcome the tumor relapse caused by antigen loss. We are working on bringing hope to those patients with such unmet medical needs.

PeproMene Bio

Company Details